Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The potential of key Alzheimer's plasma biomarkers to mimic tau PET MUBADA-based disease staging.

Alzheimer's research & therapy·2026
Same author

Longitudinal Change in Blood-Based Biomarkers and the Association With MRI-Measured Neurodegeneration in Cognitively Unimpaired Individuals.

Neurology·2026
Same author

Plasma biomarkers for Alzheimer disease: the road from laboratory results to clinical practice.

Nature reviews. Neurology·2026
Same author

The ABOARD-RWD infrastructure: Using linked real-world data to study the diagnosis and management of dementia.

Journal of Alzheimer's disease : JAD·2026
Same author

Long-term impact of disclosing amyloid PET results to individuals with subjective cognitive decline.

Alzheimer's research & therapy·2026
Same author

Soluble SORL1 in cerebrospinal fluid as a marker for functional impact of rare SORL1 variants.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Calvin Trieu1,2,3, Ellen Dicks1,2, Mardou S S A van Leeuwenstijn1,2

  • 1Alzheimer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, Noord-Holland, Netherlands.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

主观认知衰退 (SCD) 个体的灰质缩与阿尔茨海默病 (AD) 病理学有关,特别是质纤维酸蛋白 (GFAP) 水平. 血液生物标志物显示出监测SCD中大脑变化和疾病进展的潜力.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

科学领域:

  • 神经学 神经学
  • 生物标志物 生物标志物
  • 神经成像是一种神经成像.

背景情况:

  • 血基生物标志物是主观认知衰退 (SCD) 个体中阿尔茨海默病 (AD) 病理学的已知标志物.
  • 血液生物标志物的纵向变化与SCD灰色质缩之间的关联尚不清楚.
  • 这项研究调查了血液生物标志物与SCD患者皮质厚度和海马体积变化之间的关系.

研究的目的:

  • 研究血基阿尔茨海默病 (AD) 生物标志物与主观认知衰退 (SCD) 个体的灰色物质缩之间的纵向关联.
  • 为了确定基线水平或生物标志物如GFAP,pTau217和NfL的纵向变化是否与皮质厚度和海马体积的变化相关.

主要方法:

  • 167名SCD患者 (49名粉素阳性[A+],118名粉素阴性[A-]) 每两年接受血液采样,并在4.6±2.7年内重复成像.
  • 使用SIMOA测量了血液生物标志物 (Aβ42/40,pTau217,GFAP,NfL). 使用纵向FreeSurfer评估皮质厚度和海马体积.
  • 线性混合模型分析了基线生物标志物水平/斜率与大脑结构变化之间的关联.

主要成果:

  • 与SCD A-.相比,SCD A+患者的皮质厚度和海马体积随着时间的推移,与SCD A-.相比,SCD A.患者的皮质厚度和海马体积的减少更大.
  • 较高的基线GFAP和随着时间的推移增加的GFAP显著与皮质厚度和海马体积的较大减少有关.
  • 较高的基线pTau217和pTau217的增加与海马体积减少有关. 较高的基线NfL与皮质厚度和海马体积的减少相关,但没有纵向变化.
  • Aβ42/40水平 (基线或变化) 与缩无关.

结论:

  • 患有SCD的个体的灰质缩与AD相关的病理学有关,由血液生物标志物,特别是GFAP表示.
  • 基于血液的生物标志物,特别是GFAP,显示出监测SCD中的结构性大脑变化和疾病进展的潜力.
  • 这些发现支持血液生物标志物的实用性,用于跟踪认知能力下降的个体的神经退行变化.